tirzepatide bone loss Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes in obese mice via gut microbial-related metabolites New research suggests that prolonged

3: (11.4mg/100g) No

They differ by: receptor profile approval status trial design tolerability and how much real-world evidence exists today That is why the most honest ranking is not 1st, 2nd, 3rd. It is: semaglutide is the proven single-agonist benchmark tirzepatide is the current approved leader retatrutide is the Phase 3 investigational drug most likely to reshape the market if the remaining data hold Sources New England Journal of Medicine / PubMed: STEP 1 semaglutide trial FDA: Wegovy cardiovascular-risk indication and current indication summary FDA: Zepbound approval for chronic weight management Eli Lilly: SURMOUNT-5 complete results Eli Lilly: TRIUMPH-4 Phase 3 retatrutide results Eli Lilly: retatrutide Phase 3 diabetes results and dysesthesia signal Lilly FAQ: what to know about retatrutide

Some patients with incontinentia pigmenti have large deletions that remove four exons of G6PD

The largest increases in first-time CVD diagnosis following first-time GLP-1 RA prescription were seen in the group of people having overweight or BMIs between 27 to 30 (34.5% increase from 2020 to 2024)

In these trials, GLP1-RAs have consistently demonstrated benefits for both primary cardiovascular and secondary kidney outcomes